GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Enrolling by invitation · NCT05650749 · Registry updated 2026-08-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma | Eye Diseases, Hereditary, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, extraocular retinoblastoma, eye disorder, neoplasm, neuroblastoma, neuroepithelial neoplasm, ocular cancer, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma | Enrolling by invitation | Phase 1 | 2026-08-14 | NCT05650749 |
6 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Hospital of Philadelphia | 215 |
| Gilead Sciences | 180 |
| Kite, A Gilead Company | 27 |
| National Cancer Institute (NCI) | 3015 |
| Stephan Grupp MD PhD | 8 |
| University of Pennsylvania | 502 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |